文献速递脑血管病

常规使用替奈普酶进行急性缺血性卒中溶栓

Routine Use of Tenecteplase for Thrombolysis in Acute Ischemic Stroke.
PubMed 文献 · Stroke · 2021-02-16

本研究回顾性分析了2018至2020年新西兰3个中心165例接受静脉替奈普酶溶栓的连续患者,并与2个中心254例阿替普酶患者比较。结果显示替奈普酶的症状性颅内出血率、血管性水肿率和90天功能独立率与阿替普酶相当,常规使用替奈普酶可行且安全性相似。

要点

  • 替奈普酶组症状性颅内出血率为1.8%(95%CI 0.4-5.3),阿替普酶组为2.7%(95%CI 1.1-5.7),P=0.75。
  • 替奈普酶与阿替普酶在90天功能独立(mRS 0-2)率上无显著差异(61% vs 57%,P=0.47)。
  • 混合效应逻辑回归显示溶栓药物选择与症状性颅内出血或功能独立无显著关联。

核心结论

  • 常规使用替奈普酶进行卒中溶栓是可行的,其安全性和结局与阿替普酶相当。

研究设计与样本

  • 回顾性分析,纳入2018年7月14日至2020年2月29日在新西兰1个综合和2个区域卒中中心连续接受静脉替奈普酶溶栓的165例患者,并与2个其他综合卒中中心的254例阿替普酶治疗患者比较。

主要发现

  • 替奈普酶组症状性颅内出血3例(1.8% [95% CI, 0.4-5.3]),阿替普酶组7例(2.7% [95% CI, 1.1-5.7]),P=0.75。
  • 替奈普酶组血管性水肿4例(2.4% [95% CI, 0.7-6.2]),阿替普酶组1例(0.4% [95% CI, 0.01-2.2]),P=0.08。
  • 90天功能独立(mRS 0-2)替奈普酶组100例(61%),阿替普酶组140例(57%),P=0.47。
  • 混合效应逻辑回归中,替奈普酶与症状性颅内出血的OR为0.62(95% CI, 0.14-2.80),P=0.53;与功能独立的OR为1.20(95% CI, 0.74-1.95),P=0.46。

临床怎么用

  • 对于急性缺血性卒中患者,可考虑常规使用替奈普酶进行静脉溶栓,其安全性和功能结局与阿替普酶相当。

局限性

  • 本研究为回顾性分析,非随机对照设计,可能存在选择偏倚和混杂因素。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: In ischemic stroke, intravenous tenecteplase is noninferior to alteplase in selected patients and has some practical advantages. Several stroke centers in New Zealand changed to routine off-label intravenous tenecteplase due to improved early recanalization in large vessel occlusion, inconsistent access to thrombectomy within stroke networks, and for consistency in treatment protocols between patients with and without large vessel occlusion. We report the feasibility and safety outcomes in tenecteplase-treated patients. METHODS: We performed a retrospective analysis of consecutive patients thrombolyzed with intravenous tenecteplase at 1 comprehensive and 2 regional stroke centers from July 14, 2018, to February 29, 2020. We report the baseline clinical characteristics, rates of symptomatic intracranial hemorrhage, and angioedema. These were then compared with patient outcomes with those treated with intravenous alteplase at 2 other comprehensive stroke centers. Multivariable mixed-effects logistic regression models were performed assessing the association of tenecteplase with symptomatic intracranial hemorrhage and independent outcome (modified Rankin Scale score, 0-2) at day 90. RESULTS: There were 165 patients treated with tenecteplase and 254 with alteplase. Age (75 versus 74 years), sex (56% versus 60% male), National Institutes of Health Stroke Scale scores (8 versus 10), median door-to-needle times (47 versus 48 minutes), or onset-to-needle time (129 versus 130 minutes) were similar between the groups. Symptomatic intracranial hemorrhage occurred in 3 (1.8% [95% CI, 0.4-5.3]) tenecteplase patients compared with 7 (2.7% [95% CI, 1.1-5.7]) alteplase patients (P=0.75). There were no differences between tenecteplase and alteplase in the rates of angioedema (4 [2.4%; 95% CI, 0.7-6.2] versus 1 [0.4%; 95% CI, 0.01-2.2], P=0.08) or 90-day functional independence (100 [61%] versus 140 [57%], P=0.47), respectively. In mixed-effects logistic regression models, there was no significant association between thrombolytic choice and symptomatic intracranial hemorrhage (odds ratio tenecteplase, 0.62 [95% CI, 0.14-2.80], P=0.53) or functional independence (odds ratio tenecteplase, 1.20 [95% CI, 0.74-1.95], P=0.46). CONCLUSIONS: Routine use of tenecteplase for stroke thrombolysis was feasible and had comparable safety profile and outcome to alteplase.

来源:Stroke,查看原文。版权归原作者所有。

引用

  1. Zhong CS, Beharry J, Salazar D, et al. Routine Use of Tenecteplase for Thrombolysis in Acute Ischemic Stroke. Stroke. 2021. PMID: 33588597. doi:10.1161/STROKEAHA.120.030859

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。